Financial Performance - The company reported a revenue of RMB 71,123,000 for the six months ended June 30, 2025, compared to RMB 6,978,000 for the same period in 2024, representing a significant increase of 919%[10] - Gross profit for the same period was RMB 60,781,000, recovering from a gross loss of RMB 5,621,000 in 2024[10] - The net loss for the period was RMB 121,518,000, an improvement from a net loss of RMB 155,807,000 in 2024[10] - Basic and diluted loss per share was RMB 0.34, compared to RMB 0.43 in the previous year[10] - Revenue increased significantly from RMB 7.0 million for the six months ended June 30, 2024, to RMB 71.1 million for the six months ended June 30, 2025, driven by rising sales of the quadrivalent influenza virus subunit vaccine[41] - The total loss decreased by 22.0% from RMB 155.8 million for the six months ended June 30, 2024, to RMB 121.5 million for the six months ended June 30, 2025[54] - The company reported a pre-tax loss of RMB 121,518,000 for the six months ended June 30, 2025, an improvement from a loss of RMB 155,807,000 in 2024[111] - The company recorded a total comprehensive loss of RMB (121,518,000) for the six months ended June 30, 2025, compared to a loss of RMB (155,807,000) for the same period in 2024, reflecting a decrease in losses of approximately 22%[115] Research and Development - Research and development expenses were RMB 98,848,000, slightly decreased from RMB 99,865,000 in the previous year[10] - The company has two core products: a quadrivalent influenza virus subunit vaccine and a lyophilized human rabies vaccine, with 11 additional vaccines in development[11] - The quadrivalent influenza virus subunit vaccine is expected to complete safety research approval by Q4 2025, with further studies planned for 2026[12] - The company plans to initiate Phase I clinical trials for several vaccines, including a trivalent influenza virus subunit vaccine and a lyophilized human rabies vaccine, in Q4 2025[12] - The company aims to submit IND applications for multiple vaccines, including mRNA and varicella vaccines, by Q1 2026[12] - The company is developing an adjuvanted vaccine for individuals aged 65 and above, a trivalent influenza subunit vaccine for individuals aged 3 and above, and a trivalent influenza subunit vaccine (adjuvanted) for individuals aged 65 and above[16] - The company is developing a 23-valent pneumococcal polysaccharide vaccine (PPSV23) for individuals aged 2 and above, which has shown a strong immune response in Phase I clinical trials[21] - The recombinant herpes zoster vaccine is being developed for individuals aged 40 and above, with IND approvals for Phase I and II clinical trials obtained in August 2024[23] - The company is developing a 24-valent pneumococcal conjugate vaccine (PCV24) that targets 24 serotypes of pneumococcus, aiming to reduce the risk of invasive diseases such as meningitis and pneumonia[24] - The recombinant RSV vaccine is designed to protect adults, including pregnant women, from acute RSV infections and related severe lower respiratory diseases, with IND applications submitted in May and June 2025[25] - The company is currently developing an RSV-mRNA vaccine aimed at preventing acute RSV infections in individuals aged 60 and above, which is in preclinical research[26] - The company is also developing an mRNA monkeypox vaccine for individuals aged 18 and above, which is in preclinical research[27] Product Development and Approval - The four-valent influenza subunit vaccine received NDA approval from the National Medical Products Administration (NMPA) in May 2023 for individuals aged 3 and above, and is the first and only full-dose four-valent influenza subunit vaccine approved in China[16] - The company began commercialization of the four-valent influenza subunit vaccine in September 2023, with all production conducted in-house by June 30, 2025[16] - The trivalent influenza subunit vaccine aims to provide protection against two strains of influenza A (H1N1 and H3N2) and one strain of influenza B (Victoria lineage), aligning with the WHO's recommended strains for the 2024-2025 Northern Hemisphere seasonal influenza vaccine[20] - The quadrivalent influenza virus subunit vaccine has completed market access procedures in 30 provinces and has been selected by over 1,100 county-level disease control centers[34] - The company has received IND approvals for nine vaccine candidates from the National Medical Products Administration as of June 30, 2025[31] Financial Position and Cash Flow - Cash and cash equivalents amounted to RMB 108.4 million as of June 30, 2025, with expectations of generating more cash from operations through the sale of vaccines and new product launches[59] - Total current liabilities were RMB 859,880,000 as of June 30, 2025, compared to RMB 908,679,000 at the end of 2024[112] - The company’s cash and cash equivalents decreased to RMB 108,427,000 from RMB 132,194,000 in the previous year[112] - The net cash used in operating activities for the six months ended June 30, 2025, was RMB (31,882,000), an improvement compared to RMB (107,921,000) for the same period in 2024, indicating a reduction in cash outflow of about 70%[115] - The net cash used in investing activities for the six months ended June 30, 2025, was RMB (46,726,000), compared to RMB (96,716,000) in the same period of 2024, showing a reduction in cash outflow of approximately 52%[115] - The company reported financing cash inflows of RMB 54,841,000 for the six months ended June 30, 2025, a decrease from RMB 340,982,000 in the same period of 2024, indicating a decline of about 84%[115] Shareholder Structure and Ownership - As of June 30, 2025, the company’s director holds 39.93% of unlisted shares and 42.25% of H shares, indicating substantial insider ownership[83] - The company has a total of 190 patents in China, including 37 invention patents and 153 utility model patents, as of June 30, 2025[35] - Major shareholders include Jiangsu Qiaoyu and Mr. Cai, each with substantial holdings in both unlisted and H shares[87] - The company has a diverse shareholder structure with multiple entities holding significant stakes[89] - The percentage of shares held by major shareholders indicates a concentrated ownership structure, which may impact governance[87] - The company is subject to the Securities and Futures Ordinance, which governs the disclosure of shareholdings[86] - The latest data reflects the company's ongoing compliance with regulatory requirements regarding shareholder disclosures[88] Risks and Challenges - The company faces significant risks in vaccine development, including complexity, uncertainty, and high costs associated with regulatory approvals[81] - The company has limited pipeline for vaccine candidates, which may impact future revenue potential[81] - Regulatory obligations may lead to significant additional expenses even after product approval[81] - The company may face challenges in recruiting clinical trial participants, potentially delaying development activities[81] - Data collected during the R&D process may be inaccurate or incomplete, posing risks to future trials[81] - International trade policies and geopolitical factors may affect the company's business and financial performance[81] Cost Management and Expenses - Sales cost decreased by 18.3% from RMB 12.6 million for the six months ended June 30, 2024, to RMB 10.3 million for the six months ended June 30, 2025, due to improved inventory management[42] - Administrative expenses decreased by 17.6% from RMB 31.8 million for the six months ended June 30, 2024, to RMB 26.2 million for the six months ended June 30, 2025, mainly due to the continued vesting of share-based awards[51] - Total employee costs decreased to RMB 73,474,000 in 2025 from RMB 92,424,000 in 2024, marking a 20% decline[128] - The total remuneration for directors and key management personnel for the six months ended June 30, 2025, was RMB 6,058,000, a decrease of 50.9% compared to RMB 12,337,000 in 2024[156] Capital and Investments - The company raised approximately HKD 431.4 million from its global offering, with a net amount of approximately HKD 382.7 million after expenses[77] - The estimated allocation of the net proceeds from the IPO includes 63.6% for the development and registration of core products, amounting to HKD 243.4 million, expected to be utilized by the end of 2027[78] - The company has not encountered any significant labor disputes or strikes that could adversely affect its business or recruitment as of June 30, 2025[37] - There were no major investments or acquisitions during the six months ended June 30, 2025[72] Future Outlook - The company provided a positive outlook for the next quarter, projecting revenue growth of B% and an increase in user engagement metrics[168] - New product launches are expected to contribute an additional $C million in revenue, with a focus on innovative technologies[169] - The company is expanding its market presence in region D, aiming for a market share increase of E% by the end of the fiscal year[169] - Ongoing research and development efforts are focused on vaccine technology, with an investment of $F million allocated for clinical trials[169] - Strategic partnerships are being formed to leverage synergies in technology and distribution, expected to yield a combined revenue increase of H%[169] - The company has set a performance guidance of I% growth for the upcoming fiscal year, driven by new market strategies[169] - The introduction of new vaccine products is anticipated to significantly boost sales, with projected revenues of $J million in the first year[169]

2025 2025 中期報告 Interim Report China Traditional Chinese Medicine Holdings Co. Limited 2025 Interim Report 2025 中期報告 中 國 中 藥 控 股 有 限 公 司 目錄 公司資料 2 管理層討論及分析 3 其他資料 25 中期簡明合併財務報表審閱報告 28 中期簡明合併損益及其他全面收益表 30 中期簡明合併財務狀況表 31 中期簡明合併權益變動表 33 中期簡明合併現金流量表 34 中期簡明合併財務資料附註 35 公司資料 董事會 執行董事 楊 軍先生 （主席） 李鴻堅先生 彭 力先生 非執行董事 劉海建先生 李向榮先生 祖 敬先生 許京輝女士 黃 灝先生 獨立非執行董事 謝 榮先生 余梓山先生 秦 嶺先生 李偉東先生 公司秘書 伍秀薇女士 審核委員會 謝 榮先生 （主席） 祖 敬先生 余梓山先生 秦 嶺先生 李偉東先生 薪酬與考核委員會 秦 嶺先生 （主席） 謝 榮先生 余梓山先生 李偉東先生 提名委員會 楊 軍先生 （主席） 李鴻堅先生 許京輝女士 謝 榮先生 余梓山先生 秦 嶺先生 李偉東先生 ...

1792 中期報告 INTERIM REPORT 1792 RT INTERIM REPO 中期報告 2025 RT CMON Limited 目錄 1 2025年中期報告 2 公司資料 4 簡明綜合損益及其他全面收益表 5 簡明綜合財務狀況表 7 簡明綜合權益變動表 8 簡明綜合現金流量表 9 簡明綜合財務報表附註 16 管理層討論及分析 22 企業管治及其他資料 CMON Limited 公司資料 薪酬委員會 梁毓雄先生 （主席） 王宇山先生 蔡敏先生 董事會 執行董事 黃成安先生 （主席兼聯席行政總裁） 建邦先生 （聯席行政總裁） 許政開先生 （辭任自二零二五年 十一月十四日起生效） 非執行董事 蔡穩健先生 李學瑾女士 David Preti先生 （自二零二五年 四月十四日起辭任） 獨立非執行董事 王宇山先生 蔡敏先生 梁毓雄先生 審核委員會 王宇山先生 （主席） 蔡敏先生 梁毓雄先生 提名委員會 蔡敏先生 （主席） 王宇山先生 梁毓雄先生 授權代表 黃俊穎先生 （自二零二五年八月二十八日起 獲委任） 許政開先生 （辭任自二零二五年十一月 十四日起生效） 黃成安先生 （自二零二五年十一月十四日起 獲委任 ...

目錄 | 釋義 | 02 | | --- | --- | | 公司資料 | 06 | | 管理層討論與分析 | 07 | | 其他資料 | 29 | | 簡明合併財務報表審閱報告 | 35 | | 簡明合併利潤表及其他全面收益表 | 36 | | 簡明合併財務狀況表 | 38 | | 簡明合併權益變動表 | 40 | | 簡明合併現金流量表 | 42 | | 簡明合併財務報表註釋 | 45 | 01 金風科技股份有限公司 二零二五年中期報告 釋義 本半年報內，除文義另有所指外，以下詞語具有以下含義： | 「2024年度股東會」 | 公司於2025年6月26日舉行的2024年度股東會； | | --- | --- | | 「A股」 | 本公司於深交所發行上市並以人民幣買賣的普通股，每股面值以人民幣計值為 | | | 人民幣1.00元； | | 「A股股東」 | A股的持有者； | | 「《章程》」 | 本公司《章程》，經不時修訂、增補或以其他方式修改； | | 「聯繫人」 | 具有《上市規則》所賦予之含義； | | 「權益容量」 | 代表本集團所佔權益容量，通過本集團在某電力項目中之所有權百分比乘以該 | | ...

[Company Information](index=3&type=section&id=%E5%85%AC%E5%8F%B8%E8%B3%87%E6%96%99) [Board of Directors and Committees](index=3&type=section&id=%E8%91%A3%E4%BA%8B%E6%9C%83%E5%8F%8A%E5%A7%94%E5%93%A1%E6%9C%83) The company's board members changed with Mr. Lun Zhaoming and Mr. Lu Peijun resigning, and Ms. Wang Di appointed as executive director, while committee members remained stable - Executive Director Mr. Lun Zhaoming resigned effective from **January 1, 2025**, and Mr. Lu Peijun resigned effective from **September 8, 2025**[5](index=5&type=chunk) - Ms. Wang Di was appointed as an executive director effective from **May 16, 2025**[5](index=5&type=chunk) - The chairmen and members of the Audit Committee, Nomination Committee, and Remuneration Committee remained unchanged[5](index=5&type=chunk)[6](index=6&type=chunk) [Registered and Principal Places of Business](index=3&type=section&id=%E8%A8%BB%E5%86%8A%E5%8F%8A%E4%B8%BB%E8%A6%81%E7%87%9F%E6%A5%AD%E5%9C%B0%E9%BB%9E) The company's registered office is in the Cayman Islands, with its principal place of business in Dongguan, Guangdong, and Hong Kong - The registered office is located at Cricket Square, Hutchins Drive, Cayman Islands[7](index=7&type=chunk) - The principal place of business and head office in China is located at No. 1 Beihuan Road, Houjie Town, Dongguan City, Guangdong Province[10](index=10&type=chunk) - The principal place of business in Hong Kong is located at Room 1907, 19th Floor, Great Eagle Centre, 23 Harbour Road, Hong Kong[11](index=11&type=chunk) [Professional Advisors and Banks](index=4&type=section&id=%E5%B0%88%E6%A5%AD%E9%A1%A7%E5%95%8F%E5%8F%8A%E9%8A%80%E8%A1%8C) The company's auditor is BCT CPA Limited, legal counsel is Leung & Yentak Solicitors, and principal bankers include Hang Seng Bank - The auditor is BCT CPA Limited[11](index=11&type=chunk) - The legal counsel is Leung & Yentak Solicitors (for Hong Kong law)[12](index=12&type=chunk) - Principal bankers include Hang Seng Bank, Dongguan Rural Commercial Bank Houjie Branch, Industrial and Commercial Bank of China Dongguan Houjie Branch, and China Construction Bank Dongguan Houjie Branch[12](index=12&type=chunk) [Management Discussion and Analysis](index=6&type=section&id=%E7%AE%A1%E7%90%86%E5%B1%A4%E8%A8%8E%E8%AB%96%E5%8F%8A%E5%88%86%E6%9E%90) [Overall Review](index=6&type=section&id=%E6%95%B4%E4%BD%93%E6%A6%82%E8%A7%88) China's real estate market continued deep adjustments in 2025; the Group maintained its "one core, two wings" strategy focusing on residential development and urban renewal in high-value cities - China's real estate industry continued to experience deep adjustments in **2025**, with the government adhering to the "housing is for living, not for speculation; city-specific policies" policy, aiming for "stable land prices", "stable housing prices", and "stable expectations"[17](index=17&type=chunk)[20](index=20&type=chunk) - The Group maintained its "one main, one core, two wings" business structure, namely, residential development as the main business, urban renewal as the core, and cultural tourism, health, and technology innovation industries as the two wings[17](index=17&type=chunk)[21](index=21&type=chunk) - The Group's strategy is "based in the Greater Bay Area, deeply cultivating Dongguan, and expanding into South China, Central China, and East China and other high-value cities"[17](index=17&type=chunk)[21](index=21&type=chunk) [Business Review](index=6&type=section&id=%E4%B8%9A%E5%8A%A1%E5%9B%9E%E9%A1%B1) The Group's total revenue for H1 2025 was RMB **136.1 million**, up **297%**, driven by property sales, despite significant drops in contracted sales and area 2025 H1 Business Overview | Indicator | 2025 H1 (RMB million) | 2024 H1 (RMB million) | Y-o-Y Change | | :--- | :--- | :--- | :--- | | Total Revenue | 136.1 | 34.3 | +297% | | Property Sales Revenue | 117.8 | 18.213 | +547.0% | | Investment Property Rental Income | 7.1 | - | - | | Contracted Sales Amount | 1.7 | - | -97.7% | | Contracted Sales GFA | 437.1 sq.m. | - | -93.3% | | Total GFA of Properties Sold and Recognized | 23,929 sq.m. | 2,779 sq.m. | +761.0% | | Average Selling Price | 4,924 RMB/square meter | 6,554 RMB/square meter | -24.9% | 2025 H1 Property Sales Regional Distribution | City | Recognized GFA (sq.m.) | % of Total GFA | Average Selling Price (RMB/square meter) | Recognized Revenue (RMB thousand) | % of Recognized Revenue | | :--- | :--- | :--- | :--- | :--- | :--- | | Dongguan | 51 | 0.2% | 2,235 | 114 | 0.1% | | Heyuan | 22,836 | 95.5% | 5,012 | 114,450 | 97.2% | | Hengyang | 152 | 0.6% | 5,697 | 866 | 0.7% | | Changsha | 890 | 3.7% | 2,701 | 2,404 | 2.0% | | **Total** | **23,929** | **100%** | **4,924** | **117,834** | **100%** | - As of **June 30, 2025**, the Group's land reserve was approximately **2,175,219 sq.m.**, including **15** projects and **3** land parcels, distributed across **5** cities in the Greater Bay Area, Yangtze River Delta urban cluster, and Central Yangtze River urban cluster[36](index=36&type=chunk)[38](index=38&type=chunk) [Financial Review](index=12&type=section&id=%E8%B2%A1%E5%8B%99%E5%9B%9E%E9%A1%B1) H1 2025 total revenue increased by **297%** to RMB **136.1 million**, but gross profit margin fell to **13.8%**, expanding net loss to RMB **240.9 million** due to product mix and exchange losses 2025 H1 Key Financial Performance | Indicator | 2025 H1 (RMB million) | 2024 H1 (RMB million) | Y-o-Y Change | | :--- | :--- | :--- | :--- | | Total Revenue | 136.1 | 34.3 | +297% | | Gross Profit | 18.8 | 18.8 | +0.1% | | Gross Profit Margin | 13.8% | 54.8% | -41.0 percentage points | | Loss for the Period | 240.9 | 228.1 | +5.6% | | Loss Attributable to Owners of the Parent | 250.8 | 227.8 | +10.1% | | Other Income and Gains | 0.7 | 5.9 | -88.1% | | Selling and Distribution Expenses | 1.5 | 6.6 | -77.3% | | Administrative Expenses | 28.9 | 51.8 | -44.2% | | Other Expenses | 77.3 | 19.0 | +306.8% | | Share of Loss of Joint Ventures | 12.0 | 5.9 | +103.4% | | Finance Costs | 134.3 | 149.4 | -10.1% | | Income Tax Expense | 30.8 | 1.7 | +1711.8% | - The decrease in gross profit margin was primarily due to changes in the product and geographical mix of properties delivered in **2025** and the relatively lower average selling price of delivered properties[54](index=54&type=chunk)[58](index=58&type=chunk) - The decrease in other income and gains was primarily due to a decrease in interest income from joint ventures of approximately RMB **3.7 million** and a decrease in exchange gains of approximately RMB **1.5 million**[61](index=61&type=chunk)[66](index=66&type=chunk) - The increase in other expenses was primarily due to an increase in exchange losses of approximately RMB **32.5 million**[65](index=65&type=chunk)[70](index=70&type=chunk) - The increase in income tax expense was primarily due to a significant decrease in land appreciation tax provision leading to an increase in deferred income tax of approximately RMB **24.2 million**, and an increase in land appreciation tax accrual due to increased property sales of

Financial Performance - The Company's revenue for the Reporting Period was approximately HK$64.8 million, a decrease of 1.5% compared to HK$65.8 million for the six months ended June 30, 2024[11]. - The Group recorded a loss before tax of approximately HK$212.6 million, a reduction of 22.6% from the loss of approximately HK$274.7 million in the same period ended June 30, 2024[11]. - The income tax credit for the Reporting Period was approximately HK$14.3 million, leading to a loss attributable to owners of the Company of approximately HK$198.7 million, down from HK$251.7 million for the same period in 2024[12]. - The Group recorded a loss of approximately HK$196.0 million for the segment, a decrease of approximately 23.6% compared to a loss of approximately HK$256.6 million in the same period ended June 30, 2024[43]. - The Group incurred a net loss of approximately HK$198,268,000 for the six months ended 30 June 2025[168]. - The total comprehensive income for the period attributable to owners of the Company was a loss of HK$248,506,000, slightly better than the loss of HK$255,651,000 in the previous year[158]. - Basic loss per share improved to HK$3.78 from HK$4.79 year-over-year, indicating a reduction in per-share losses[154]. Revenue Sources - Revenue from the shopping malls is derived from rental income and property management services[18]. - The revenue generated from the Shopping Mall Businesses in the PRC was approximately HK$38.5 million, primarily from rental income and property management services[26]. - Revenue from the flooring materials trading business decreased by approximately 3.6% to approximately HK$13.3 million compared to the same period ended June 30, 2024[45]. - Revenue from the medical equipment trading business decreased by approximately 13.4% to approximately HK$12.9 million compared to the same period ended June 30, 2024[46]. - Rental income from leases increased to HK$16,540,000, up 20.43% from HK$13,752,000 in 2024[186]. - The properties investment segment generated revenue of HK$38,589,000, while the financial services and assets management segment contributed HK$6,000[195]. Investment Properties and Acquisitions - A decrease in fair value of investment properties was approximately HK$83.1 million due to a sluggish retail shop rental market[14]. - The acquisitions of Anyang, Jinzhou, and Guangzhou shopping malls completed in 2021 have expanded the geographical coverage and scale of the Group's shopping mall businesses[23][24]. - As of June 30, 2025, the fair values of investment properties were approximately HK$268 million for Anyang Shopping Mall, HK$498 million for Jinzhou Shopping Mall, and HK$520 million for Guangzhou Shopping Mall[26][27]. Financial Liabilities and Debt - The total debt financing of the Group as of June 30, 2025, was approximately HK$1,472.2 million, compared to approximately HK$1,435.3 million as of December 31, 2024[60]. - The principal of the defaulted bank loan by the Borrowers amounted to RMB3,400,000,000 as of June 30, 2025[70]. - The Group's consolidated net liabilities increased to approximately HK$1,984.5 million from HK$1,736.4 million as of December 31, 2024, representing an increase of approximately HK$248.1 million[58]. - The Group's current liabilities amounted to approximately HKD 3,237,923,000, with total liabilities of approximately HKD 1,984,505,000, including overdue bank borrowings of approximately HKD 1,471,430,000[170]. Cost Management and Operational Strategies - The Company actively implements a continuous cost-saving plan to mitigate losses[11]. - The Group's diversified business strategy aims to enhance the effectiveness and cost-efficiency of promotional campaigns and marketing activities for its shopping malls[23][24]. - The Group plans to reduce debts and guarantee obligations of Guangzhou and Jinzhou Shopping Malls through collaboration with banks and stakeholders, ensuring healthy operations[107]. Employee and Corporate Governance - As of June 30, 2025, the Group had 171 employees, an increase from 163 employees as of December 31, 2024, with approximately 8.8% located in Hong Kong[93]. - The company complied with all applicable provisions of the Corporate Governance Code during the reporting period[137]. - The Audit Committee, consisting of three independent non-executive Directors, reviewed the unaudited condensed consolidated financial statements for compliance with applicable accounting standards[148]. Market Conditions and Economic Outlook - The PRC economy's GDP grew by 5.3% year-on-year in the first half of the year, indicating resilience and potential for economic development[96]. - Total retail sales of consumer goods in the PRC exceeded RMB 24 trillion, reflecting a 5% year-on-year increase[96]. - The external environment remains uncertain, particularly due to ongoing tariff disputes initiated by the US[97]. Share Capital and Compliance - As of June 30, 2025, the total number of issued shares of the Company is 5,250,019,852[124]. - Satinu Resources Group Ltd. holds 3,937,234,889 shares, representing approximately 74.99% of the Company's issued share capital[126]. - The Company has adopted a Share Option Scheme allowing for the issuance of up to 125,091,243 shares, representing 10% of the issued shares as of September 17, 2015[131]. - The Company aims to ensure that any judgments related to the transferred liabilities are correctly allocated to the appropriate entities[114].

先 聲 藥 業 集 團 有 限 公 司 （ 於 香 港 註 冊 成 立 的 有 限 公 司 ） 股 份 代 號 : 2025 中期報告 目錄 公司資料 2 財務概要 4 公司概覽 5 管理層討論及分析 7 企業管治及其他資料 34 獨立核數師審閱報告 46 合併損益表 47 合併損益及其他全面收益表 48 合併財務狀況表 49 合併權益變動表 51 簡明合併現金流量表 54 未經審核中期財務報告附註 55 公司資料 執行董事 任晉生先生 （董事長兼首席執行官） 唐任宏先生 萬玉山先生 王熙女士 獨立非執行董事 宋瑞霖先生 汪建國先生 王新華先生 宋嘉桓先生 審計委員會 王新華先生 （主席） 宋瑞霖先生 汪建國先生 薪酬與考核委員會 汪建國先生 （主席） 任晉生先生 萬玉山先生 王新華先生 宋嘉桓先生 提名委員會 宋瑞霖先生 （主席） 任晉生先生 王熙女士 汪建國先生 宋嘉桓先生 戰略委員會 公司資料 主要往來銀行 中國銀行股份有限公司 南京江北新區分行 中國江蘇省 南京市浦口區 夢澤路33號2幢101室 招商銀行股份有限公司 南京解放路支行 中國江蘇省 南京市秦淮區 解放路53號 核數師 任晉生先生 （主席） ...

* 股份代號：6661 （於中華人民共和國註冊成立的股份有限公司） 2025 中期報告 * 僅供識別 Customer Service Center 客 服 服 务 中 心 峋䄎挼奠 粁㞀椳嬈✂꿟긲 目錄 02 公司資料 03 釋義 06 管理層討論與分析 14 企業管治及其他資料 18 獨立審閱報告 20 中期簡明綜合損益表 21 中期簡明綜合全面收益表 22 中期簡明綜合財務狀況表 24 中期簡明綜合權益變動表 26 中期簡明綜合現金流量表 28 中期簡明綜合財務資料附註 公司資料 董事會 執行董事 汪驊先生 （主席） 王韜先生 （於2025年4月25日獲委任） 孫曉慧女士 楊帆先生 （於2025年4月25日辭任） 非執行董事 王鵬先生 宮羅建先生 （於2025年4月25日獲委任） 劉建鋒先生 （於2025年4月25日辭任） 獨立非執行董事 張立憲先生 劉雪樵博士 周鑫發先生 監事 邢燕女士 蔡銳先生 沈佳輝先生 （於2025年3月26日獲委任） 徐國新先生 （於2025年3月26日辭任） 審核委員會 張立憲先生 （主席） 劉雪樵博士 周鑫發先生 提名委員會 周鑫發先生 （主席） 張立憲先生 劉雪樵博士 ...

Financial Performance - The company reported revenue of RMB 5,850 million for the first half of 2025, a decrease of 2.6% compared to RMB 6,007 million in the same period of 2024[7]. - Gross profit for the first half of 2025 was RMB 848 million, down 15.4% from RMB 1,003 million in the first half of 2024[7]. - Net profit attributable to the company's owners was RMB 641 million, a decrease of 6.6% from RMB 687 million in the previous year[7]. - The group's revenue for the reporting period was RMB 5,850.2 million, a decrease of RMB 156.4 million or 2.6% compared to RMB 6,006.6 million in the same period of 2024[25]. - The gross profit for the group was RMB 847.9 million, a decrease of RMB 155.2 million or 15.5% compared to RMB 1,003.1 million in 2024[27]. - The group's net profit for the period was RMB 723.8 million, a decrease of RMB 19.6 million or 2.6% compared to RMB 743.4 million in the same period of 2024[39]. Production and Sales - The production volume of fertilizers for the first half of 2025 was 967,647 tons, a slight decrease of 0.6% from 973,476 tons in the same period of 2024[8]. - The sales volume of chemical products increased by 8.6% to 726,174 tons in the first half of 2025, compared to 668,460 tons in the previous year[9]. - In the first half of the year, the company produced 968,000 tons of urea, 781,000 tons of methanol, 450,000 tons of phosphate and compound fertilizers, and 132,000 tons of acrylonitrile series products[21]. - The company sold 996,000 tons of urea, 726,000 tons of methanol, 386,000 tons of phosphate and compound fertilizers, and 127,000 tons of acrylonitrile series products in the first half of the year[21]. Market Prices - The average market price of urea in the first half of the year was RMB 1,804 per ton, a year-on-year decrease of RMB 434 per ton, representing a decline of 19%[15]. - The average market price of monoammonium phosphate was RMB 3,268 per ton, up 6.48% year-on-year[16]. - The average market price of diammonium phosphate was RMB 3,954 per ton, up 1.59% year-on-year[16]. - The average price of acrylonitrile in the first half of the year was RMB 9,350.41 per ton, down 5.4% from RMB 9,888.10 per ton in the same period last year[19]. Assets and Liabilities - The company's total assets increased to RMB 24,571 million as of June 30, 2025, compared to RMB 24,076 million at the end of 2024[7]. - As of June 30, 2025, the group had total interest-bearing liabilities of RMB 2,335.2 million, with a capital debt ratio of 10.7%[43]. - Total liabilities increased to RMB 4,999,064 thousand as of June 30, 2025, compared to RMB 4,569,034 thousand as of December 31, 2024, representing an increase of 9.4%[81]. - Current liabilities rose to RMB 3,204,407 thousand as of June 30, 2025, up from RMB 2,512,948 thousand as of December 31, 2024, indicating a growth of 27.5%[81]. Cash Flow and Investments - The group reported a cash flow from operating activities of RMB 533,057,000 for the six months ended June 30, 2025, compared to RMB 679,928,000 for the same period in 2024, reflecting a decrease of 21.6%[127]. - The company’s investment activities resulted in a net cash outflow of RMB 249,564 thousand for the six months ended June 30, 2025, compared to a net inflow of RMB 126,333 thousand for the same period in 2024[86]. - The group reported capital expenditures totaling RMB 78.76 million, with significant investments including RMB 27.83 million for the second phase of the Pisha gypsum dry stacking project and RMB 19.48 million for the underground mining project with an annual capacity of 1.6 million tons[41]. Corporate Governance and Compliance - The company has adopted accounting principles and standards reviewed by the audit committee, with no disagreements noted regarding the accounting treatment for the interim results for the six months ending June 30, 2025[59]. - The company has complied with all provisions of the Corporate Governance Code during the six months ending June 30, 2025, except as noted[60]. Future Outlook and Strategy - The company plans to continue expanding its market presence and sales channels while enhancing operational efficiency amid a challenging market environment[11]. - Key focus areas for the company in the second half of 2025 include enhancing equipment management systems, improving marketing effectiveness, and advancing research on low-carbon natural gas utilization projects[57]. - The industry outlook for the second half of 2025 indicates a continued oversupply in the urea market, with price pressures expected in the fourth quarter due to new capacity releases and declining demand[56].

Drama Production and Content Strategy - By the end of June 2025, the Group has produced and distributed a total of 26 high-quality drama series, with 24 being original series where the Group acted as the lead/sole investor and executive producer[7]. - The Group's original drama series include popular titles such as "A Love for Separation," "Nothing but Thirty," and "Novoland: Eagle Flag," focusing on contemporary themes like family life and female empowerment[9]. - The Group is committed to diversified growth strategies, exploring new avenues such as content marketing, short drama series, overseas business, and IP derivative development to maximize the commercial value of proprietary IP rights[10]. - The original drama series "A Dream within a Dream" achieved significant viewership, with over 8 billion views on Douyin, ranking TOP1 among drama series during the same period[35]. - Several new projects are in preparation, scheduled to start shooting in the second half of 2025, including "A Journey to Glow" and "Showdown"[35]. - The Group aims to produce over 200 episodes of long drama series throughout 2025, focusing on premium original content[47]. - The Group is actively exploring the production and distribution of mini and short drama series in niche languages, with several projects currently in production[43]. - The Group's short commercial-break dramas achieved significant popularity, with multiple titles ranking TOP1 on various platforms[41]. Financial Performance - Revenue for the six months ended June 30, 2025, amounted to approximately RMB 401.3 million, representing an increase of 109% from approximately RMB 192.5 million for the same period in 2024[24]. - Gross profit for the same period was approximately RMB 101.0 million, an increase of 140% from approximately RMB 43.0 million in 2024[24]. - Net profit for the six months ended June 30, 2025, was approximately RMB 11.3 million, compared to a net loss of approximately RMB 52.9 million for the same period in 2024[24]. - Adjusted net profit for the same period was approximately RMB 14.4 million, a turnaround from an adjusted net loss of approximately RMB 49.4 million in 2024[24]. - The Group's total revenue increased by 109% from RMB192.5 million for the six months ended June 30, 2024, to RMB401.3 million for the six months ended June 30, 2025, primarily due to the launch of the 40-episode drama "A Dream within a Dream"[55]. - Gross profit rose by 135% from RMB43.0 million for the six months ended June 30, 2024, to RMB100.99 million for the six months ended June 30, 2025[58]. - The gross profit margin improved by 2.8 percentage points from 22.4% for the six months ended June 30, 2024, to 25.2% for the six months ended June 30, 2025[59]. - The Group's cost of sales increased by 101% from RMB149.5 million for the six months ended June 30, 2024, to RMB300.3 million for the six months ended June 30, 2025[57]. - Other income and gains decreased by 39.4% from RMB46.5 million for the six months ended June 30, 2024, to RMB28.2 million for the six months ended June 30, 2025[63]. - Administrative expenses decreased by 24.6% from RMB99.0 million for the six months ended June 30, 2024, to RMB74.7 million for the six months ended June 30, 2025[65]. - Finance costs increased by 56.7% to RMB2.3 million for the six months ended June 30, 2025, from RMB1.5 million for the six months ended June 30, 2024[66]. - The Group recorded a net profit of RMB11.3 million for the six months ended June 30, 2025, compared to a net loss of RMB52.9 million for the six months ended June 30, 2024[76]. - Income tax expense decreased to RMB1.5 million for the six months ended June 30, 2025, from RMB6.3 million for the six months ended June 30, 2024, due to the utilization of deductible losses from previous years[68]. - Revenue growth was driven by the broadcast of quality drama series and improved financial performance from new business lines such as short drama series[84]. Overseas Business and Distribution - The Group's overseas distribution revenue recorded notable growth year-on-year, with the first overseas localized long drama series recently broadcasting[27]. - The Group's overseas business revenue exceeded RMB 33 million in the first half of 2025, approximately 2.5 times higher than the same period in 2024[42]. - The original drama series "A Dream within a Dream" ranked TOP1 on the iQIYI International platform across eleven countries and regions in the first half of 2025[43]. Employee and Workforce Diversity - As of June 30, 2025, the Group had 185 employees, with approximately 76.8% being female, reflecting a commitment to workforce diversity[50][52]. Corporate Governance and Compliance - The company has adopted the Model Code for Securities Transactions by Directors and confirmed compliance by all Directors for the six months ended June 30, 2025[122]. - The company will continue to review its corporate governance practices to ensure compliance with the CG Code[117]. - The company has established an Audit Committee to oversee financial reporting, internal controls, and risk management, comprising one non-executive Director and two independent non-executive Directors[126]. - The Board believes that the current structure of the Chairman and CEO roles, held by Mr. Su, will not impair the balance of power and authority within the company[116]. - The overall strategic and key business policies of the company are made collectively after thorough discussion among all Board members and senior managers[116]. Shareholder Interests and Options - The interests of directors and chief executives in the company include Mr. Su, Ms. Chen, and Ms. Xu, each holding approximately 37.94% of the shares through controlled corporations[142]. - As of June 30, 2025, Mr. Su directly holds 71,136,000 shares in the company[144]. - Faye Free Flight Limited and A&O Investment Limited, both wholly owned by Ms. Chen and Ms. Xu respectively, each hold 33,014,520 shares in the company[144]. - The direct interest held by Mr. Su, Ms. Chen, and Ms. Xu in Shanghai Linmon is 56.93%[149]. - The Pre-IPO Share Option Scheme allows for a maximum of 14,680,471 shares to be issued, which is 4.06% of the total issued shares as of the interim report date[165]. - As of June 30, 2025, 11,906,964 options have been granted under the Pre-IPO Share Option Scheme, representing 3.29% of the total issued shares[165]. - The 2024 Share Option Scheme allows for a maximum of 36,045,882 shares to be issued, representing 9.97% of the total issued shares of 361,575,527 as of the interim report date[190]. - The maximum number of shares issuable to service provider participants is 18,022,941, which is 4.98% of the total issued shares[190]. - The option exercise price will be determined by the Board and must be at least the higher of a specified minimum[200].